N-(2-(5-(5-(2-Cyclopentylethyl)-1,2,4-oxadiazol-3-yl)-1H-benzo[d]imidazole-1-yl)ethyl)-4-iodobenzamide

ID: ALA5285772

Chembl Id: CHEMBL5285772

Max Phase: Preclinical

Molecular Formula: C25H26IN5O2

Molecular Weight: 555.42

Names and Identifiers

Canonical SMILES:  O=C(NCCn1cnc2cc(-c3noc(CCC4CCCC4)n3)ccc21)c1ccc(I)cc1

Standard InChI:  InChI=1S/C25H26IN5O2/c26-20-9-6-18(7-10-20)25(32)27-13-14-31-16-28-21-15-19(8-11-22(21)31)24-29-23(33-30-24)12-5-17-3-1-2-4-17/h6-11,15-17H,1-5,12-14H2,(H,27,32)

Standard InChI Key:  SCSAVEAKHXRMNM-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA5285772

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 555.42

Molecular Weight (Monoisotopic): 555.1131

AlogP: 5.24

#Rotatable Bonds: 8

Polar Surface Area: 85.84

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 5.30

CX LogP: 5.75

CX LogD: 5.75

Aromatic Rings: 4

Heavy Atoms: 33

QED Weighted: 0.30

Np Likeness Score: -2.01

References

1. Qiu J, Zou Y, Li S, Yang L, Qiu Z, Kong F, Gu X..  (2022)  Discovery of benzimidazole substituted 1, 2, 4-oxadiazole compounds as novel anti-HBV agents with TLR8-agonistic activities.,  244  [PMID:36228413] [10.1016/j.ejmech.2022.114833]

Source

Source(1):

• Scientific Literature